ADAPT TAVR -Just Better, page-19

thank you very much for sharing that research. Much appreciated and adds great value to the discussion.

I thought this section reveals the path WP is following and to hang his hat on imo...


Admedus has made several patent applications and wants to get to a higher number by the end of the year. TAVR is a $5 billion space, 80% of it owned by Edwards Lifesciences Corp.and Medtronic PLC. The devices reach $30,000 each and it is a growing sector.

"We can build a whole TAVR. We've got a prototype. But it would have to be a co-promotion, co-development deal with one of the big companies." Paterson has his eye on a candidate, a large firm sitting on the edge of the space, having tried already to get in. He plans an approach in first-quarter 2018, and expects a deal to be done very quickly. (my bold)

Admedus' tissue now has 10 years of data that show that the company has been able to get rid of most of the calcium binding sites, not an easy thing to achieve. There's more too, as Admedus looks to mitral valves.